goodthingswithdata.com

Works index

Published on this site

2026-10-21

I created this website, in part, to showcase the arc of my creative and intellectual contributions. This page indexes the full caboodle. You can arrange by domain or work type. You can search by citations element, including my coauthors and title words.

Domains

I organize my works into domains that correspond to my professional arc over time. My URL paths derive from these domain names.

descriptor (domain) subdomain(s)
Early work (early) perinatal · enviro-hlth
Women’s health and HIV (women-hlth-hiv) women-hlth · hiv
Research and public health ethics (ethics) ethics-research · ethics-pub-hlth
Regulation and policy (regs) reg-research · reg-admin
Tuberculosis clinical trials (tb-trials) tb-trials
Tuberculosis case-finding and diagnostics (tb-find) tb-find
Tuberculosis surveillance and strategy (tb-surv) tb-surv · tb-strategy
Covid-19 (covid) covid
Data practice, methods, and techniques (data-practice) data-practice
Data culture, strategy, and workforce (data-culture) data-culture · data-info
Data and health equity (data-equity) data-equity
Personal material (personal) personal

You can see a list of my works organized by domain.

Work types

I also organize my works by type, as follows:

work type examples
long-form essays (lf) A culture for doing good things with data
short-form posts (sf) Rhetoric · Sledgehammer
presentations (pr) Find TB to stop TB · Composing data graphics as a literary act
publications (pu) A critical history of individual and collective ethics · Justifying research risks (MDR TB)

I hope to expand the collection of work types to include teaching material and other resources. You can see a list of my works organized by type.

Early work (5)

  • Klemm R, Mason R, Heilig C, Cowan D. The effect of imputation of exposure estimates on the association between fine particulate matter and mortality. Annals of Epidemiology. 2000-10; 10(7): 477–478.Elsewhere on the web (opens in a new tab)
  • Klemm RJ, Mason RM, Heilig CM, Neas LM, Dockery DW. Is daily mortality associated specifically with fine particles? Data reconstruction and replication of analyses. Journal of the Air and Waste Management Association. 2000-07; 50(7): 1215–1222.Elsewhere on the web (opens in a new tab)
  • Gould J, Blackwell T, Heilig C, Axley M. Utility of percentage of births to teenagers as a surrogate for the teen birth rate. American Journal of Public Health. 1998-06; 88(6): 908–912.Elsewhere on the web (opens in a new tab)
  • Heilig CM, Gould JB. Timeliness in risk-adjusted newborn mortality statistics [Technical report]. Berkeley, CA: Maternal and Child Health Program, School of Public Health, University of California, Berkeley; 1997-07.
  • Gould JB, Heilig CM, Blackwell TL. Perinatal profiles of California regions and hospitals, 1989–1993 [Technical report]. Berkeley, CA: Maternal and Child Health Program, School of Public Health, University of California, Berkeley; 1997-03.

Women's health and HIV (19)

  • Millett GA, Jeffries WL, Peterson JL, Malebranche DJ, Lane T, Flores SA, Fenton KA, Wilson PA, Steiner R, Heilig CM. Common roots: a contextual review of HIV epidemics in black men who have sex with men across the African diaspora. Lancet. 2012-07; 380(9839): 411–423.Elsewhere on the web (opens in a new tab)
  • Millett GA, Peterson JL, Flores SA, Hart TA, Jeffries WL, Wilson PA, Rourke SB, Heilig CM, Elford J, Fenton KA, Remis RS. Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. Lancet. 2012-07; 380(9839): 341–348.Elsewhere on the web (opens in a new tab)
  • Corneli AL, Sorenson JR, Bentley ME, Henderson GE, Michael Bowling J, Nkhoma J, Moses A, Zulu C, Chilima J, Ahmed Y, …, Heilig CM, …. Improving participant understanding of informed consent in an HIV-prevention clinical trial: A comparison of methods. AIDS and Behavior. 2012-02; 16(2): 412–421.Elsewhere on the web (opens in a new tab)
  • Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, Rompalo AM, Cu-Uvin S, Duerr A. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstetrics and Gynecology. 2009-01; 113(1): 26–31.Elsewhere on the web (opens in a new tab)
  • Farr SL, Jamieson DJ, Rivera HV, Ahmed Y, Heilig CM. Risk factors for cesarean delivery among Puerto Rican women. Obstetrics and Gynecology. 2007-06; 109(6): 1351–1357.Elsewhere on the web (opens in a new tab)
  • Tohill BC, Heilig CM, Klein RS, Rompalo A, Cu-Uvin S, Piwoz EG, Jamieson DJ, Duerr A. Nutritional biomarkers associated with gynecological conditions among US women with or at risk of HIV infection. American Journal of Clinical Nutrition. 2007-05; 85(5): 1327–1334.Elsewhere on the web (opens in a new tab)
  • Corneli AL, Bentley ME, Sorenson JR, Henderson GE, Van Der Horst C, Moses A, Nkhoma J, Tenthani L, Ahmed Y, Heilig CM, Jamieson DJ. Using formative research to develop a context-specific approach to informed consent for clinical trials. Journal of Empirical Research on Human Research Ethics. 2006-12; 1(4): 45–60.Elsewhere on the web (opens in a new tab)
  • Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, Shah KV, Klein RS, Cu‐Uvin S, Schuman P, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. International Journal of Cancer. 2006-10; 119(7): 1623–1629.Elsewhere on the web (opens in a new tab)
  • Koshiol J, Schroeder J, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, Shah KV, Klein RS, Cu-Uvin S, Schuman P, et al. Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. American Journal of Epidemiology. 2006-07-15; 164(2): 176–183.Elsewhere on the web (opens in a new tab)
  • Duerr A, Paramsothy P, Jamieson DJ, Heilig CM, Klein RS, Cu-Uvin S, Schuman P, Anderson JR, HIV Epidemiology Research Study. Effect of HIV infection on atypical squamous cells of undetermined significance. Clinical Infectious Diseases. 2006-03-15; 42(6): 855–861.Elsewhere on the web (opens in a new tab)
  • Anderson JR, Paramsothy P, Heilig C, Jamieson DJ, Shah K, Duerr A, HIV Epidemiology Research (HER) Study Group. Accuracy of Papanicolaou test among HIV-infected women. Clinical Infectious Diseases. 2006-02-15; 42(4): 562–568.Elsewhere on the web (opens in a new tab)
  • Costello C, Nelson K, Suriyanon V, Sennun S, Tovanabutra S, Heilig C, Shiboski S, Jamieson D, Robison V, Rungruenthanakit K, Duerr A. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. International Journal of Epidemiology. 2005-06-01; 34(3): 577–584.Elsewhere on the web (opens in a new tab)
  • Kingkeow D, Heilig CM, Costello C, Sennun S, Suriyanon V, Rungruengthanakit K, Taejaroenkul S, Nelson KE, Duerr A. Lymphocyte homeostasis in HIV-infected northern Thais. AIDS Research and Human Retroviruses. 2004-06; 20(6): 636–641.Elsewhere on the web (opens in a new tab)
  • Paramsothy P, Duerr A, Heilig CM, Cu-Uvin S, Anderson JR, Schuman P, Klein RS. Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. Journal of Acquired Immune Deficiency Syndromes. 2004-04; 35(5): 484–491.Elsewhere on the web (opens in a new tab)
  • Tohill BC, Heilig CM, Klein RS, Rompalo A, Cu-Uvin S, Brown W, Duerr A. Vaginal flora morphotypic profiles and assessment of bacterial vaginosis in women at risk for HIV infection. Infectious Disease in Obstetrics and Gynecology. 2004-01; 12(3-4): 121–126.Elsewhere on the web (opens in a new tab)
  • Duerr A, Heilig CM, Meikle SF, Cu-Uvin S, Klein RS, Rompalo A, Sobel JD. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus–infected women: Risk factors and severity. Obstetrics and Gynecology. 2003-03; 101(3): 548–556.Elsewhere on the web (opens in a new tab)
  • Phelps RM, Smith DK, Heilig CM, Gardner LI, Carpenter CCJ, Klein RS, Jamieson DJ, Vlahov D, Schuman P, Holmberg SD, HER Study Group. Cancer incidence in women with or at risk for HIV. International Journal of Cancer. 2001-12-01; 94(5): 753–757.Elsewhere on the web (opens in a new tab)
  • Gielen AC, Fogarty LA, Armstrong K, Green BM, Cabral R, Milstein B, Galavotti C, Heilig CM. Promoting condom use with main partners: A behavioral intervention trial for women. AIDS and Behavior. 2001-09; 5(3): 193–204.Elsewhere on the web (opens in a new tab)
  • Fogarty LA, Heilig CM, Armstrong K, Cabral R, Galavotti C, Gielen AC, Green BM. Long-term effectiveness of a peer-based intervention to promote condom and contraceptive use among HIV-positive and at-risk women. Public Health Reports. 2001-01; 116(1_suppl): 103–119.Elsewhere on the web (opens in a new tab)

5 further presentations in this domain, not yet titled, are not listed.

Research and public health ethics (4)

  • Hey S, Heilig CM, Weijer C. Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program. Trials. 2013; 14(1): 159.Elsewhere on the web (opens in a new tab)
  • Lee LM, Heilig CM, White A. Ethical justification for conducting public health surveillance without patient consent. American Journal of Public Health. 2012-01; 102(1): 38–44.Elsewhere on the web (opens in a new tab)
  • Heilig CM, Sweeney P. Ethics in public health surveillance. In: Principles and practice of public health surveillance. 3rd ed. New York, NY: Oxford University Press; 2010.Elsewhere on the web (opens in a new tab)
  • Heilig CM, Weijer C. A critical history of individual and collective ethics in the lineage of Lellouch and Schwartz. Clinical Trials. 2005-06; 2(3): 244–253.Elsewhere on the web (opens in a new tab)

10 further presentations in this domain, not yet titled, are not listed.

Regulation and policy (5)

  • Heilig CM, Lee LM. Speeding up public health science: Reducing processing time under the Paperwork Reduction Act. Government Information Quarterly (submitted). 2012-02-24.On this site (opens in a new tab)
  • Centers for Disease Control and Prevention. Human research protections [CDC policy CDC-SA-2010-01]. 2010-07-29.
  • Centers for Disease Control and Prevention. Distinguishing public health research and public health nonresearch [CDC policy CDC-SA-2010-02]. 2010-07-29.
  • Heilig CM. OMB PRA time-in-process, October 2003–December 2009. 2010-01-21.
  • Report of the OMB PRA/privacy/confidentiality assessment and strategy workgroup. Office of the Chief Science Officer, Centers for Disease Control and Prevention; 2007-04-30.

35 further presentations in this domain, not yet titled, are not listed.

Tuberculosis clinical trials (14)

  • Scott NA, Lee KK, Sadowski C, Kurbatova EV, Goldberg SV, Nsubuga P, Kitshoff R, Whitelaw C, Thuy HN, Batra K, …, Heilig CM, …. Optimizing drug inventory management with a web-based information system: The TBTC Study 31/ACTG A5349 experience. Contemporary Clinical Trials. 2021-06; 105: 106377.Elsewhere on the web (opens in a new tab)
  • Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang K-C, Chen M, Cotton M, Dooley KE, …, Heilig CM, …. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemporary Clinical Trials. 2020-03; 90: 105938.Elsewhere on the web (opens in a new tab)
  • Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, et al. Xpert MTB/RIF assay shows faster clearance of Mycobacterium tuberculosis DNA with higher levels of rifapentine exposure. Journal of Clinical Microbiology. 2016-12; 54(12): 3028–3033.Elsewhere on the web (opens in a new tab)
  • Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. American Journal of Respiratory and Critical Care Medicine. 2015-02-01; 191(3): 333–343.Elsewhere on the web (opens in a new tab)
  • Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Hamilton CD, Bock N, Narita M, Wing D, Hershfield E, et al. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. International Journal of Tuberculosis and Lung Disease. 2014-05-01; 18(5): 571–580.Elsewhere on the web (opens in a new tab)
  • Heilig CM, Feng P-JI, Joloba ML, Johnson JL, Morgan K, Gitta P, Boom WH, Mayanja-Kizza H, Eisenach KD, Bozeman L, Goldberg SV. How we determined the most reliable solid medium for studying treatment of tuberculosis. Tuberculosis. 2014-05; 94(3): 317–322.Elsewhere on the web (opens in a new tab)
  • Joloba ML, Johnson JL, Feng P-JI, Bozeman L, Goldberg SV, Morgan K, Gitta P, Boom HW, Heilig CM, Mayanja-Kizza H, Eisenach KD. What is the most reliable solid culture medium for tuberculosis treatment trials? Tuberculosis. 2014-05; 94(3): 311–316.Elsewhere on the web (opens in a new tab)
  • Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. International Journal of Tuberculosis and Lung Disease. 2013-12-01; 17(12): 1531–1537.Elsewhere on the web (opens in a new tab)
  • Hales CM, Heilig CM, Chaisson R, Leung CC, Chang KC, Goldberg SV, Gordin F, Johnson JL, Muzanyi G, Saukkonen J, et al. The association between symptoms and microbiologically defined response to tuberculosis treatment. Annals of the American Thoracic Society. 2013-02; 10(1): 18–25.Elsewhere on the web (opens in a new tab)
  • Padayatchi N, Mac Kenzie WR, Hirsch-Moverman Y, Feng P-J, Villarino E, Saukkonen J, Heilig CM, Weiner M, El-Sadr WM. Lessons from a randomised clinical trial for multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease. 2012-12-01; 16(12): 1582–1587.Elsewhere on the web (opens in a new tab)
  • Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng P-J, Moro R, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the Tuberculosis Trials Consortium. Journal of Infectious Diseases. 2012-10-01; 206(7): 1030–1040.Elsewhere on the web (opens in a new tab)
  • Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, Dunbar D, Jost KC, Diem L, Metchock B, Eisenach K, et al. Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLOS ONE. 2011-04-11; 6(4): e18358.Elsewhere on the web (opens in a new tab)
  • Heilig CM, Chia D, El-Sadr WM, Hirsch-Moverman Y, Mac Kenzie WR, Saukkonen J, Villarino ME, Padayatchi N. Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis. IRB: Ethics and Human Research 33, no. 4 (July-August 2011): 10-17. 2011; 33(4): 10–17.Elsewhere on the web (opens in a new tab)
  • Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2009-08-01; 180(3): 273–280.Elsewhere on the web (opens in a new tab)

39 further presentations in this domain, not yet titled, are not listed.

Tuberculosis case-finding and diagnostics (20)

  • Song R, Click ES, McCarthy KD, Heilig CM, Mchembere W, Smith JP, Fajans M, Musau SK, Okeyo E, Okumu A, et al. Sensitive and feasible specimen collection and testing strategies for diagnosing tuberculosis in young children. JAMA Pediatrics. 2021-05-03; 175(5): e206069.Elsewhere on the web (opens in a new tab)
  • Barr DA, Lewis JM, Feasey N, Schutz C, Kerkhoff AD, Jacob ST, Andrews B, Kelly P, Lakhi S, Muchemwa L, …, Heilig CM, …. Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data. Lancet Infectious Diseases. 2020-06; 20(6): 742–752.Elsewhere on the web (opens in a new tab)
  • Warria K, Nyamthimba P, Chweya A, Agaya J, Achola M, Reichler M, Cowden J, Heilig CM, Borgdorff MW, Cain KP, Yuen CM. Tuberculosis disease and infection among household contacts of bacteriologically confirmed and non‐confirmed tuberculosis patients. Tropical Medicine and International Health. 2020-06; 25(6): 695–701.Elsewhere on the web (opens in a new tab)
  • Mchembere W, Agaya J, Yuen CM, Okelloh D, Achola M, Opole J, Cowden J, Muttai H, Heilig CM, Borgdorff MW, Cain KP. High yield of new HIV diagnoses during active case-finding for tuberculosis. AIDS. 2019-12-01; 33(15): 2431–2435.Elsewhere on the web (opens in a new tab)
  • Yuen CM, Agaya J, Mchembere W, Okelloh D, Achola M, Opole J, Cowden J, Heilig CM, Borgdorff MW, Cain KP. Optimizing the efficiency of tuberculosis active case-finding in health facilities and communities. International Journal of Tuberculosis and Lung Disease. 2019-07-01; 23(7): 844–849.Elsewhere on the web (opens in a new tab)
  • Okelloh D, Achola M, Opole J, Ogwang C, Agaya J, Sifuna P, Mchembere W, Cowden J, Heilig CM, Borgdorff MW, et al. Lessons learned from community-based tuberculosis case-finding in western Kenya. Public Health Action. 2019-06-21; 9(2): 53–57.Elsewhere on the web (opens in a new tab)
  • Modi S, Cavanaugh JS, Shiraishi RW, Alexander HL, McCarthy KD, Burmen B, Muttai H, Heilig CM, Nakashima AK, Cain KP. Performance of clinical screening algorithms for tuberculosis intensified case finding among people living with HIV in western Kenya. PLOS ONE. 2016-12-09; 11(12): e0167685.Elsewhere on the web (opens in a new tab)
  • Auld SC, Lee SH, Click ES, Miramontes R, Day CL, Gandhi NR, Heilig CM. IFN-γ release assay result is associated with disease site and death in active tuberculosis. Annals of the American Thoracic Society. 2016-12; 13(12): 2151–2158.Elsewhere on the web (opens in a new tab)
  • Cavanaugh JS, Modi S, Musau S, McCarthy K, Alexander H, Burmen B, Heilig CM, Shiraishi RW, Cain K. Comparative yield of different diagnostic tests for tuberculosis among people living with HIV in western Kenya. PLOS ONE. 2016-03-29; 11(3): e0152364.Elsewhere on the web (opens in a new tab)
  • Kim L, Moonan PK, Heilig CM, Woodruff RSY, Kammerer JS, Haddad MB. Factors associated with recurrent tuberculosis more than 12 months after treatment completion. International Journal of Tuberculosis and Lung Disease. 2016-01-01; 20(1): 49–56.Elsewhere on the web (opens in a new tab)
  • Sharma A, Musau S, Heilig CM, Okumu AO, Opiyo EO, Basiye FL, Miruka FO, Kioko JK, Sitienei JK, Cain KP. Assessing the effect of decentralisation of laboratory diagnosis for drug-resistant tuberculosis in Kenya. International Journal of Tuberculosis and Lung Disease. 2015-11-01; 19(11): 1348–1353.Elsewhere on the web (opens in a new tab)
  • Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, …, Heilig CM, …. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respiratory Medicine. 2015-03; 3(3): 201–209.Elsewhere on the web (opens in a new tab)
  • Auld SC, Click ES, Heilig CM, Miramontes R, Cain KP, Bisson GP, Mac Kenzie WR. Association between tuberculin skin test result and clinical presentation of tuberculosis disease. BMC Infectious Diseases. 2013-12; 13(1): 460.Elsewhere on the web (opens in a new tab)
  • Auld SC, Click ES, Heilig CM, Miramontes R, Cain KP, Bisson GP, Mac Kenzie WR. Tuberculin skin test result and risk of death among persons with active TB. PLOS ONE. 2013-11-11; 8(11): e78779.Elsewhere on the web (opens in a new tab)
  • Oramasionwu GE, Heilig CM, Udomsantisuk N, Kimerling ME, Eng B, Nguyen HD, Thai S, Keo C, McCarthy KD, Varma JK, Cain KP. The utility of stool cultures for diagnosing tuberculosis in people living with the human immunodeficiency virus. International Journal of Tuberculosis and Lung Disease. 2013-08-01; 17(8): 1023–1028.Elsewhere on the web (opens in a new tab)
  • Kim L, Heilig CM, McCarthy KD, Phanuphak N, Chheng P, Kanara N, Quy HT, Sar B, Cain KP, Varma JK. Symptom screen for identification of highly infectious tuberculosis in people living with HIV in Southeast Asia. Journal of Acquired Immune Deficiency Syndromes. 2012-08-15; 60(5): 519–524.Elsewhere on the web (opens in a new tab)
  • Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, Grant AD, Churchyard GJ, Kimerling M, Shah S, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: Individual participant data meta-analysis of observational studies. PLOS Medicine. 2011-01-18; 8(1): e1000391.Elsewhere on the web (opens in a new tab)
  • Heilig CM. Find TB to stop TB: how science has improved global guidelines for curtailing the TB/HIV syndemic. Presented at: Citizen Science, Bard College; 2011-01-13.On this site (opens in a new tab)
  • Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, Kimerling ME, Chheng P, Thai S, Sar B, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. New England Journal of Medicine. 2010-02-25; 362(8): 707–716.Elsewhere on the web (opens in a new tab)
  • Monkongdee P, McCarthy KD, Cain KP, Tasaneeyapan T, Dung NH, Lan NTN, Yen NTB, Teeratakulpisarn N, Udomsantisuk N, Heilig C, Varma JK. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. American Journal of Respiratory and Critical Care Medicine. 2009-11-01; 180(9): 903–908.Elsewhere on the web (opens in a new tab)

22 further presentations in this domain, not yet titled, are not listed.

Tuberculosis surveillance and strategy (7)

  • Althomsons SP, Winglee K, Heilig CM, Talarico S, Silk B, Wortham J, Hill AN, Navin TR. Using machine learning techniques and national tuberculosis surveillance data to predict excess growth in genotyped tuberculosis clusters. American Journal of Epidemiology. 2022-10-20; 191(11): 1936–1943.Elsewhere on the web (opens in a new tab)
  • Nnadi CD, Anderson LF, Armstrong LR, Stagg HR, Pedrazzoli D, Pratt R, Heilig CM, Abubakar I, Moonan PK. Mind the gap: TB trends in the USA and the UK, 2000–2011. Thorax. 2016-04; 71(4): 356–363.Elsewhere on the web (opens in a new tab)
  • Sharma A, Bloss E, Heilig CM, Click ES. Tuberculosis caused by Mycobacterium africanum, United States, 2004–2013. Emerging Infectious Diseases. 2016-03; 22(3): 396–403.Elsewhere on the web (opens in a new tab)
  • Heilig CM. A scrappy little division that cares a lot about data: a vision for data sciences in DTBE. Presented at: Division of Tuberculosis Elimination, CDC; 2014-03-06.On this site (opens in a new tab)
  • Report of the Division of Tuberculosis Elimination think tank. Centers for Disease Control and Prevention; 2013-08-15.
  • Heilig CM. Data whispering: gently taming complex laboratory data for tuberculosis research. Presented at: Division of Tuberculosis Elimination, CDC; 2013-03-14.On this site (opens in a new tab)
  • Willis MD, Winston CA, Heilig CM, Cain KP, Walter ND, Mac Kenzie WR. Seasonality of Tuberculosis in the United States, 1993-2008. Clinical Infectious Diseases. 2012-06-01; 54(11): 1553–1560.Elsewhere on the web (opens in a new tab)

4 further presentations in this domain, not yet titled, are not listed.

Covid-19 (4)

  • Armstead TL, Castelin K, Cairns CP, Skillman M, Lamia TL, Heilig CM, Dauphin LA. Effects of investments from the Centers for Disease Control and Prevention’s COVID-19 Health Disparities Grant on health departments’ capacity to address public health emergencies. Public Health Reports. 2025-01-24: 1–7.Elsewhere on the web (opens in a new tab)
  • Lee S, Almendares O, Prince-Guerra J, Anderson M, Heilig CM, Tate JE, Kirking HL. Performance of existing and novel symptom- and antigen testing–based COVID-19 case definitions in a community setting. American Journal of Epidemiology. 2023-02-24; 192(3): 438–447.Elsewhere on the web (opens in a new tab)
  • Wong KK, Heilig CM, Hause A, Myers TR, Olson CK, Gee J, Marquez P, Strid P, Shay DK. Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020–January, 2022: an observational cohort study. Lancet Digital Health. 2022-09; 4(9): e667–e675.Elsewhere on the web (opens in a new tab)
  • Reses HE, Fajans M, Lee SH, Heilig CM, Chu VT, Thornburg NJ, Christensen K, Bhattacharyya S, Fry A, Hall AJ, et al. Performance of existing and novel surveillance case definitions for COVID-19 in household contacts of PCR-confirmed COVID-19. BMC Public Health. 2021-12; 21(1): 1747.Elsewhere on the web (opens in a new tab)

2 further presentations in this domain, not yet titled, are not listed.

Data and health equity (1)

13 further presentations in this domain, not yet titled, are not listed.

Data practice, methods, and techniques (33)

57 further presentations in this domain, not yet titled, are not listed.

Data culture, strategy, and workforce (13)

36 further presentations in this domain, not yet titled, are not listed.

Personal material (8)